Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outs...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2016-01, Vol.21 (5), p.455-459
Main Authors: Kim, Uh Jin, Won, Eun-Jeong, Kee, Seung-Jung, Jung, Sook-In, Jang, Hee-Chang
Format: Article
Language:English
Subjects:
Antiviral Agents - administration & dosage
Coronavirus Infections - diagnostic imaging
Coronavirus Infections - drug therapy
Coronavirus Infections - virology
Drug Therapy, Combination
Humans
Interferon-alpha - administration & dosage
Lopinavir - administration & dosage
Male
Middle Aged
Middle East Respiratory Syndrome Coronavirus - drug effects
Middle East Respiratory Syndrome Coronavirus - genetics
Middle East Respiratory Syndrome Coronavirus - isolation & purification
Republic of Korea
Ribavirin - administration & dosage
Ritonavir - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP3002